Jpmorgan Chase & CO Avrobio, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$1.22 - $1.62 $101,916 - $135,331	-83,538 Reduced 99.66%	282 $0
Q3 2023 Nov 14, 2023	SELL	$0.98 - $1.62 $56,780 - $93,861	-57,939 Reduced 40.87%	83,820 $129,000
Q2 2023 Aug 11, 2023	SELL	$0.58 - $1.31 $38,407 - $86,748	-66,220 Reduced 31.84%	141,759 $134,000
Q1 2023 May 11, 2023	BUY	$0.76 - $1.82 $140,129 - $335,573	184,381 Added 781.34%	207,979 $207,000
Q4 2022 Feb 13, 2023	SELL	$0.64 - $0.91 $28,843 - $41,011	-45,068 Reduced 65.63%	23,598 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $1.39 Million - $2.28 Million	-2,051,378 Reduced 96.76%	68,666 $44,000
Q2 2022 Aug 11, 2022	BUY	$0.75 - $1.33 $94,239 - $167,118	125,653 Added 6.3%	2,120,044 $1.95 Million
Q1 2022 May 11, 2022	SELL	$1.29 - $4.04 $3.28 Million - $10.3 Million	-2,542,040 Reduced 56.04%	1,994,391 $2.63 Million
Q4 2021 Feb 10, 2022	SELL	$3.45 - $6.05 $252,439 - $442,684	-73,171 Reduced 1.59%	4,536,431 $17.5 Million
Q3 2021 Nov 12, 2021	BUY	$5.53 - $9.28 $25.5 Million - $42.8 Million	4,609,602 New	4,609,602 $25.7 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.